/Merck%20%26%20Co%20Inc%20billboard-by%20monticello%20via%20Shutterstock.jpg)
With a market cap of $307.3 billion, Merck & Co., Inc. (MRK) develops and markets a broad portfolio of human health pharmaceuticals and vaccines across areas such as oncology, infectious diseases, cardiometabolic disorders, and immunology, alongside a robust animal health business serving livestock and companion animals.
Companies valued at more than $200 billion are generally classified as “mega-cap” stocks, and Merck & Co. fits this criterion perfectly. The company also advances innovation through strategic collaborations and licensing agreements with leading biopharmaceutical partners to develop next-generation therapies worldwide.
Shares of the Rahway, New Jersey-based company have decreased marginally from its 52-week high of $124.19. MRK stock has increased 23.5% over the past three months, exceeding the State Street Health Care Select Sector SPDR ETF’s (XLV) 1.9% gain over the same time frame.
Longer term, shares of the company have soared 35.9% over the past 52 weeks, compared to XLV’s 7.2% return over the same time frame. Moreover, MRK stock is up 17.8% on a YTD basis, outperforming XLV’s 2.2% rise.
The stock has been trading above its 50-day and 200-day moving averages since October 2025.
Shares of MRK rose 2.2% on Feb. 3 after the company delivered a stronger-than-expected Q4 2025 adjusted EPS of $2.04 and revenue of $16.4 billion on Feb. 3. Investors were encouraged by continued strength in Keytruda, whose Q4 sales rose 7% to $8.37 billion and full-year sales reached $31.7 billion.
In comparison, rival Amgen Inc. (AMGN) has lagged behind MRK stock. AMGN stock has returned 16.5% on a YTD basis and 23.1% over the past 52 weeks.
Despite the stock’s outperformance, analysts remain cautiously optimistic about its prospects. MRK stock has a consensus rating of “Moderate Buy” from 28 analysts in coverage, and the mean price target of $126.76 is a premium of 2.4% to current levels.
